Mutant human factor IX with an increased resistance to inhibition by heparin
The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance to inhibition by heparin. Methods of making and using this composition for the therapeutic intervention of hemophilia are disclosed.
1. A mutant human factor IX comprising a mutation in the heparin binding domain which decreases its affinity for heparin as compared to wild-type human factor IX, wherein said mutation is a mutation of the amino acid residue 298, 303, 304, 312, 315, 447, 450, 456, or 458 of SEQ ID NO: 2.
2. The mutant human factor IX of claim 1 , wherein said mutation further comprises a substitution of arginine for an alanine at amino acid residue 385 of SEQ ID NO: 2.
3. A mutant human factor IX having a mutation at amino acid residue 450 of SEQ ID NO: 2, wherein said mutation decreases the affinity of said mutant human factor IX for heparin as compared to wild-type human factor IX.
4. The mutant human factor IX of claim 3 , wherein said mutation is a substitution of the arginine at amino acid residue 450 of SEQ ID NO: 2 to any other amino acid.
5. The mutant human factor IX of claim 4 , wherein arginine at amino acid residue 450 of SEQ ID NO: 2 is substituted with an alanine.
6. A method of treating a subject having hemophilia comprising administering to said subject a composition comprising a mutant human factor IX of claim 1 , in an amount effective to promote blood clotting in said subject.
7. The method of claim 6 , wherein said mutant human factor IX comprises a mutation of the amino acid located at residue 450 of SEQ ID NO:2.
8. The method of claim 7 , wherein the mutant human factor IX comprises a mutation of arginine to an alanine at amino acid residue 450 of SEQ ID NO:2.
9. The method of claim 6 , further comprising administering to said subject a composition comprising one or more additional blood clotting factors other than said mutant human factor IX.
10. The method of claim 6 , wherein said hemophilia is hemophilia B.
11. A pharmaceutical composition comprising the mutant human factor IX of any one of claims 1 through 5 and a pharmaceutically acceptable carrier, excipient, or diluent.